US2017000825A1PendingUtilityA1

Human facilitating cells

49
Assignee: UNIV LOUISVILLE RES FOUND INCPriority: May 30, 2008Filed: Sep 16, 2016Published: Jan 5, 2017
Est. expiryMay 30, 2028(~1.8 yrs left)· nominal 20-yr term from priority
Inventors:Suzanne T. IldstadMary Jane Elliott
A61P 37/00A61P 7/00A61P 7/06A61P 3/10A61P 37/06A61P 37/02A61P 35/02A61P 25/28A61P 3/00A61P 31/12A61P 31/14A61P 35/00A61P 31/18A61P 25/00A61P 1/16C12N 2501/505A61K 35/28C12N 5/0652C12N 5/0647A61K 35/12C12N 2501/599C12N 2501/515A61K 40/50A61K 40/418A61K 40/32A61K 40/22A61K 40/11A61K 40/10A61K 2239/38C12N 5/0636C12N 5/0634
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A cellular composition comprising at least about 30% human facilitating cells (hFCs), wherein said hFCs comprise cells having a phenotype of CD8+/alpha beta TCR−/CD56 dim/neg  and cells having a phenotype of CD8+/alpha beta TCR−/CD56 bright . 
     
     
         2 . The cellular composition of  claim 1 , wherein said cells having a phenotype of CD8+/alpha beta TCR−/CD56 dim/neg  are predominantly CD3 epsilon+/CD19−. 
     
     
         3 . The cellular composition of  claim 1 , wherein said cells having a phenotype of CD8+/alpha beta TCR−/CD56 bright  are predominantly CD3 epsilon−/CD19+. 
     
     
         4 . The cellular composition of  claim 1 , wherein said hFCs comprise cells having a phenotype of CD8+/alpha beta TCR−/delta gamma TCR+/CD3 epsilon+/CD19+. 
     
     
         5 . The cellular composition of  claim 1 , wherein said hFCs comprise cells having a phenotype of CD8+/alpha beta TCR−/B220+/CD11c+/CD11b−. 
     
     
         6 . The cellular composition of  claim 1 , wherein about 48% of said hFCs are CD8+/alpha beta TCR−/CD3 epsilon+, about 33% of said hFCs are CD8+/alpha beta TCR−/CD19+, about 44% of said hFCs are CD11c+, about 40% of said hFCs are CD11b+, about 42% of said hFCs are Foxp3, and about 30% of said hFCs are HLA-DR. 
     
     
         7 . The cellular composition of  claim 6 , wherein about 25% of said hFCs are CD8+/alpha beta TCR−/IFN-gamma and about 31% of said hFCs are CD8+/alpha beta TCR−/CXCR4. 
     
     
         8 . The cellular composition of  claim 1  comprising at least about 40% of the hFCs. 
     
     
         9 . The cellular composition of  claim 1  comprising at least about 50% of the hFCs. 
     
     
         10 . The cellular composition of  claim 1  comprising at least about 60% of the hFCs.

Join the waitlist — get patent alerts

Track US2017000825A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.